Bone drugs' safety doubted

Share this article:
A new U.S. Food and Drug Administration analysis raises questions about long-term effectiveness among women of the widely prescribed osteoporosis drugs known as bisphosphonates.

The safety of the bone-building drugs, which include brands such as Boniva and Reclast, has been a topic of debate. The FDA's analysis found that after three to five years of use, bisphosphonates offer little to no benefit.

FDA reviewers said it's possible long-term use of the drugs could actually weaken bones, leading to adverse events such as femur fractures and esophageal cancer.
Share this article:
close

Next Article in News

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.